NOVEL DELIVERY SYSTEMS - ORAL TRANSMUCOSAL AND INTRANASAL TRANSMUCOSAL

During the past 2 decades, anesthesiologist have been provided with a number of new, potent opioid analgesics and sedative/hypnotics, as well as an increased understanding of the pharmacokinetic and pharmacodynamic principles that govern their action and disposition. These developments have suggested that the skin and the buccal and nasal mucous membranes may have use as alternate routes of analgesic and anesthetic drug delivery. A novel transmucosal delivery system for fentanyl has recently been developed by incorporating the drug into dissolvable matrix on a stick called an "oralete." Oral transmucosal fentanyl citrate has been evaluated as a premedication in the pediatric population and as an analgesic for acute postoperative and emergency room pain, procedural pain, and breakthrough cancer pain by using fentanyl. Increases in plasma fentanyl and onset of clinical effect are rapid (20-40 min) with this formulation. A potential advantage is the apparent ease of titration to a sedative or analgesic end point. This system may improve premedication, acute postoperative analgesia, and chronic pain therapy in various clinical settings. Delivery of opioids through the nasal mucosa also has been recently investigated. In one study, sufentanil was administered (1.5, 3.0, or 4.5-mu/kg) to 80 children ranging in age from 6 mo to 7 yr. Easy separation from parents was achieved in 86% of the children 10 min following administration of the premedication. Unfortunately, 61% of the children cried after drug administration, and side effects included reduced ventilatory compliance (chest-wall rigidity) with higher doses (3.0 and 4.5-mu-g/kg). Nevertheless, nasal transmucosal drug delivery may have value, especially in frightened or uncooperative children.